References

Amabile, G., E. Stefano, I. Bianco, M.C. Aliquo and P. Giunti et al., 1987. Electrophysiological (EEG, BAEP, VEP) study in patients with β-thalassemia major. Acta Neurol. Belgica, 87: 181-190.

Angelucci, E., G. Barosi, C. Camaschella, M.D. Cappellini and M. Cazzola et al., 2008. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica, 93: 741-752.

Azarkeivan, A., A. Mehrvar, M. Faranoush, P. Vosough and N. Mehrvar et al., 2009. Cardiac involvement in patients with transfusion dependent Thalassemia. Res. J. Biol. Sci., 4: 195-199.

Bentur, Y., G. Koren, A. Tesoro, H. Carley, N. Olivieri and M.H. Freedman, 1990. Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity. Clin. Pharmacol. Therapeut., 47: 478-482.

Cappellini, M.D. and A. Piga, 2008. Current status in iron chelation in hemoglobinopathies. Curr. Mol. Med., 8: 663-674.

Economou, M., D.I. Zafeiriou, E. Kontopoulos, N. Gompakis and A. Koussi et al., 2006. Neurophysiologic and intellectual evaluation of β-thalassemia patients. Brain Dev., 28: 14-18.

Freedman, M.H., M. Boyden, M. Taylor and B. Skarf, 1988. Neurotoxicity associated with deferoxamine therapy. Toxicology, 49: 283-290.

Gelmi, C., C. Borgna-Pignatti, S. Franchin, M. Tacchini and F. Trimarchi, 1988. Electroretinographic and visual-evoked potential abnormalities in patients with β-thalassemia major. Ophthalmologica, 196: 29-34.

Karimi, M., A.A. Asadi-Pooya, B. Khademi, K. Asadi-Pooya and H. Yarmohammadi, 2002. Evaluation of the incidence of sensorineural hearing loss in β-thalassemia major patients under regular chelation therapy with desferrioxamine. Acta Haematol., 108: 79-83.

Levine, J.E., A. Cohen, M. MacQueen, M. Martin and P.J. Giardina, 1997. Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment. J. Pediatr. Hematol. Oncol., 19: 139-141.

Marciani, M.G., P. Cianciulli, N. Stefani, F. Stefanini and L. Peroni et al., 1991. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: An electrophysiological study of cerebral and visual function. Haematologica, 76: 131-134.

Mehrvar, A., A. Azarkeivan, M. Faranoush, N. Mehrvar, J. Saberinedjad, R. Ghorbani and P. Vosough, 2008. Endocrinopathies in patients with transfusion-dependent β-thalassemia. Pediatr. Hematol. Oncol., 25: 187-194.

Olivieri, N.F., J.R. Buncic, E. Chew, T. Gallant and R.V. Harrison et al., 1986. Visual and auditory neurotoxicity in patients receiving sub-cutaneous deferoxamine infusions. N. Engl. J. Med., 314: 869-873.

Shamsian, B.S., A. Aminasnafi, H. Moghadassian, L. Gachkar and M.T. Arzanian et al., 2008. Sensory neural hearing loss in β-thalassemia major patients treated with deferoxamine. Pediatr. Hematol. Oncol., 25: 502-508.

Taher, A., Z. Bashshur, W. Shamseddeen, R. Abdulnour, E. Aoun, S. Koussa and P. Baz, 2006. Ocular findings among thalassemia patients. Am. J. Ophthalmol., 142: 704-705.

Taylor, M.J., N.K. Keenan, T. Gallant, B. Skarf, M.H. Freedman and W.J. Logan, 1987. Subclinical VEP abnormalities in patients on chronic deferoxamine therapy: Longitudinal studies. Electroencephalogr. Clin. Neurophysiol., 68: 81-87.

Triantafyllou, N., M. Fisfis, G. Sideris, D. Triantafyllou and A. Rombos et al., 1991. Neurophysiological and neuro-otological study of homozygous β-thalassemia under long-term Desferrioxamine (DFO) treatment. Acta Neurol. Scand., 83: 306-308.

Wong, V., A. Li and A.C. Lee, 1993. Neurophysiologic study of β-thalassemia patients. J. Child Neurol., 8: 330-335.

Zafeiriou, D.I., A.A. Kousi, C.T. Tsantali, E.E. Kontopoulos, P.A. Augoustidou-Savvopoulou, P.D. Tsoubaris and M.A. Athanasiou, 1998. Neurophysiologic evaluation of long-term desferrioxamine therapy in β-thalassemia patients. Pediatr. Neurol., 18: 420-424.

Zafeiriou, D.I., M. Prengler, N. Gombakis, K. Kouskouras and M. Economou et al., 2004. Central nervous system abnormalities in asymptomatic young patients with Sbeta-thalassemia. Ann. Neurol., 55: 835-839.